Chlormethine/Mechlorethamine Gel for the Treatment of Cutaneous T-Cell Lymphoma

Evaluating the response patterns and safety of chlormethine/mechlorethamine gel for patients with mycosis fungoides
Chlormethine (also known as mechlorethamine) gel is a skin-directed chemotherapy that was specifically developed for the treatment of patients with mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma. Described below are two studies describing the efficacy of chlormethine/mechlorethamine gel and the lack of evidence on systemic absorption.
Patterns of response over time to mechlorethamine gel in patients with mycosis fungoides is not well-documented. Using a by-time approach, analysis of clinical response data showed three general response patterns, with response rates recorded as early as 1 month and peaking at 10 months. A third of patients could expect a very good/complete response within 1 year.
It is unknown whether mechlorethamine gel is absorbed systemically. Plasma samples were derived from two studies testing a once daily administration of the gel (at concentrations of 0.02% and 0.04%) and blood parameters assessed. No alterations were observed and chlormethine gel was concluded to pose no risk of systemic absorption even after long-term treatment.
The infographic has been created with the support of Helsinn Healthcare SA.
Site provided by Springer Healthcare. Part of the Springer Nature Group.